Tarun Tyagi

Tarun Tyagi

Auto-generated profile, based on publicly available information

Tarun Tyagi

Defence Institute of Physiology and Allied Sciences, DRDO, Delhi, India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NGNeha Gupta
Neha Gupta
ASAnita Sahu
Anita Sahu
APAmit Prabhakar
Amit Prabhakar
TCTathagata Chatterjee
Tathagata Chatterjee
TTTarun Tyagi
Tarun Tyagi
MAMohammad Zahid Ashraf
Mohammad Zahid Ashraf
Significance: Hypoxia predisposes otherwise healthy individuals to venous thrombosis, but the underlying mechanism has been unclear. Our study revealed a causal role for nucleotide binding domain, leucine-rich-containing family, pyrin domain containing 3 (NLRP3) inflammasome and IL-1β during hypoxia-induced venous thrombosis. We further show a direct association between NLRP3 and hypoxia-inducible factor 1-alpha (HIF-1α) during these conditions. Specific interventions within the hypoxia–HIF-1α–NLRP3–IL-1β axis in the venous milieu significantly reduced venous thrombosis in our animal model. Notably, we also observed modulation of similar pathways in patients diagnosed with altitude-induced venous thrombosis. Our study thus revealed thrombosis at high altitude to be centrally regulated by a complex network of coagulatory and inflammatory processes, critically linked through HIF-1α.

20 February 2014 in Blood
Verified
Journal Article
Closed access
PDF file
TTTarun Tyagi
Tarun Tyagi
SAShadab Ahmad
Shadab Ahmad
NGNeha Gupta
Neha Gupta
ASAnita Sahu
Anita Sahu
YAYasmin Ahmad
Yasmin Ahmad
MAMohammad Z. Ashraf
Mohammad Z. Ashraf
Oxygen-compromised environments, such as high altitude, air travel, and sports, and pathological conditions, such as solid tumors, have been suggested to be prothrombotic. Despite the indispensable role of platelets in thrombus formation, the studies linking hypoxia, platelet reactivity, and thrombus formation are limited. In the present study, platelet proteome/reactivity was analyzed to elucidate the acute hypoxia-induced prothrombotic phenotype. Rats exposed to acute simulated hypoxia (282 torr/8% oxygen) demonstrated a decreased bleeding propensity and increased platelet reactivity. Proteomic analysis of hypoxic platelets revealed 27 differentially expressed proteins, including those involved in coagulation. Among these proteins, calpain small subunit 1, a 28-kDa regulatory component for calpain function, was significantly upregulated under hypoxic conditions. Moreover, intraplatelet Ca2+ level and platelet calpain activity were also found to be in accordance with calpain small subunit 1 expression. The inhibition of calpain activity demonstrated reversal of hypoxia-induced platelet hyperreactivity. The prothrombotic role for calpain was further confirmed by an in vivo model of hypoxia-induced thrombosis. Interestingly, patients who developed thrombosis while at extreme altitude had elevated plasma calpain activities and increased soluble P-selectin level. In summary, this study suggests that augmented calpain activity is associated with increased incidence of thrombosis under hypoxic environments. Key Points Hypoxia induces altered platelet proteome/reactivity, which correlates with a prothrombotic phenotype. CAPNS1-dependent calpain activity in platelet activation cascade is associated with hypoxia-induced thrombogenesis.

1 December 2017 in EBioMedicine
Verified
Journal Article
Open access
ASAnita Sahu
Anita Sahu
PJPrabhash Kumar Jha
Prabhash Kumar Jha
APAmit Prabhakar
Amit Prabhakar
HSHeisnam Dinesh Singh
Heisnam Dinesh Singh
NGNeha Gupta
Neha Gupta
ZAZahid Ashraf
Zahid Ashraf
Venous thromboembolism (VTE), the third leading cardiovascular complication, requires more understanding at molecular levels. Here, we have identified miR-145 as a key molecule for regulating thrombus formation in venous thrombosis (VT) employing network based bioinformatics approach and in vivo experiments. Levels of miR-145 showed an inverse correlation with thrombus load determined by coagulation variables. MiRNA target prediction tools and in vitro study identified tissue factor (TF) as a target gene for miR-145. The restoration of miR-145 levels in thrombotic animals via in vivo miR-145 mimic delivery resulted in decreased TF level and activity, accompanied by reduced thrombogenesis. MiR-145 levels were also reduced in VT patients and correlated with increased TF levels in patients, thereby, confirming our preclinical findings. Our study identifies a previously undescribed role of miRNA in VT by regulating TF expression. Therefore, restoration of miR-145 levels may serve as a promising therapeutic strategy for management of VT.

1 June 2019 in EBioMedicine
Verified
Journal Article
Open access
KJKanika Jain
Kanika Jain
TTTarun Tyagi
Tarun Tyagi
KPKanchi Patell
Kanchi Patell
YXYi Xie
Yi Xie
AKAnis John Kadado
Anis John Kadado
JHJohn Hwa
John Hwa
Aging is a complex physiological phenomenon, intricately associated with cardiovascular pathologies, where platelets play a central pathophysiological role. Although antiplatelets are commonly employed to prevent and treat major adverse cardiovascular events, aging associated intraplatelet changes remain largely unexplored. Platelets were studied in high cardiovascular risk patients (aged 40-100 years) comparing them to younger healthy subjects. This was followed by cross sectional and longitudinal mice studies. Flow cytometry, biochemical and molecular assays were used to study platelets comprehensively. CVD Patients were categorized in the age groups 40-59, 60-79, and 80-100 years. Progressive decline in platelet health was observed in the 40-79 years age cohort, marked by increase in oxidative stress, hyperactivation and apoptotic markers. Paradoxically, this was reversed in patients aged above 79 years and the improved platelet phenotype was associated with lower oxidative damage. The platelets from the very old (80-100 year) group were found to be preloaded with increased antioxidants, which also contributed to higher resistance against induced redox insults. Cross sectional mouse studies excluded the effect of comorbidities and medications. Longitudinal mouse studies implicate an adaptive increase in antioxidant levels as the mechanism. We report a novel age associated, non-linear redox regulation in platelets in both humans and mice. In advanced age, there occurs an adaptive increase in platelet antioxidants, reducing the intracellular ROS and leading to a healthier platelet phenotype. Clinically, our results advocate the use of less aggressive antiplatelet therapies for CVD in the elderly population. FUND: Study funded by NIH-NHLBI, RO1-HL122815 and RO1-HL115247.

29 July 2019 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
FEFatemehsadat Esteghamat
Fatemehsadat Esteghamat
JBJames S. Broughton
James S. Broughton
ESEmily Smith
Emily Smith
RCRebecca Cardone
Rebecca Cardone
TTTarun Tyagi
Tarun Tyagi
AMArya Mani
Arya Mani

28 October 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TTTarun Tyagi
Tarun Tyagi
KJKanika Jain
Kanika Jain
TYTimur Yarovinsky
Timur Yarovinsky
MCMichael Chiorazzi
Michael Chiorazzi
JDJing Du
Jing Du
JHJohn Hwa
John Hwa
Current understanding of tumor immunosuppressive mechanisms forms the basis for modern day immunotherapies. Immunoregulatory role of platelets in cancer remains largely elusive. Platelets from non-small cell lung cancer (NSCLC) patients revealed a distinct activation phenotype. TREM-like transcript 1 (TLT-1), a platelet protein, was increased along with enhanced extracellular release from NSCLC platelets. The increased platelet TLT-1 was also evident in humanized mice with patient-derived tumors. In immunocompetent mice with syngeneic tumors, TLT-1 binding to T cells, in vivo, led to suppression of CD8 T cells, promoting tumor growth. We identified direct interaction between TLT-1 and CD3ε on T cells, implicating the NF-κB pathway in CD8 T cell suppression. Anti–TLT-1 antibody rescued patients’ T cells from platelet-induced suppression ex vivo and reduced tumors in mice in vivo. Clinically, higher TLT-1 correlated with reduced survival of NSCLC patients. Our findings thus identify TLT-1 as a platelet-derived immunosuppressor that suppresses CD8 T cells and demonstrate its therapeutic and prognostic significance in cancer.